# Kaltura, Inc.

Type: Company (KLTR)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/kaltura-inc
Canonical HTML page: https://getbiobrief.com/entity/kaltura-inc

## Timeline

- **2026-03-19**: Q4 2025 Earnings Call — Management discussed clinical progress of Lomecel-B and financial outlook.
- **2026-03-12**: Capital Raise — Entry into a material definitive agreement for the sale of unregistered equity securities.
- **2026-03-09**: NASDAQ Compliance Notice — Longeveron received notice of failure to satisfy NASDAQ listing rules.

## Recent coverage (1 stories)

### Longeveron Navigates Capital Constraints Amid Lomecel-B Clinical Progress
2026-03-19 13:50:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
Full story: https://getbiobrief.com/story/longeveron-q4-2025-earnings-clinical-milestones-financial-headwinds

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.